Who is sponsoring NCT04600544?

NCT04600544 is sponsored by Novosibirsk State University.

What drugs are being tested in NCT04600544?

Interventions in NCT04600544: Non-interventional.

What condition does NCT04600544 study?

NCT04600544 studies Intervertebral Disc Degeneration, Genetic Predisposition to Disease.

Is NCT04600544 still recruiting?

NCT04600544 is currently completed. Last updated 24 December 2024.

Last reviewed 2024-12-24 · How we verify

NCT04600544: RuDDS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Russian Disc Degeneration Study

Completed Last updated 24 December 2024

What this trial tests

trial testing Non-interventional in Intervertebral Disc Degeneration in 1,070 participants. Completed in 10 December 2024.

Timeline

16 October 2020

Primary endpoint
19 October 2022

10 December 2024

Quick facts

Lead sponsor	Novosibirsk State University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,070
Start date	16 October 2020
Primary completion	19 October 2022
Estimated completion	10 December 2024
Sites	3 locations across Russia

Drugs / interventions tested

Non-interventional

Conditions studied

Intervertebral Disc Degeneration — all drugs for Intervertebral Disc Degeneration →
Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →

Sponsor

Novosibirsk State University

Who can join

Adults 18 to 75, any sex, with Intervertebral Disc Degeneration or Genetic Predisposition to Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to establish disease-oriented biobank to facilitate research in biology of the lumbar disc degeneration. Diverse biological samples (whole blood, plasma, disc tissue) along with MRI imaging, clinical, socio-demographic and various omics data (e.g. genomic and transcriptomic) will be available for researchers and clinicians for a variety of further multi-omics studies. It will lay the groundwork for the development of early diagnostics of DDD and its personalized treatment. The study is planned to enroll up to 1,100 patients with different grades of lumbar disc degeneration. It is planned to recruit patients within 36 months.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A protocol for recruiting and analyzing the disease-oriented Russian disc degeneration study (RuDDS) biobank for functional omics studies of lumbar disc degeneration.
Leonova ON, Elgaeva EE, Golubeva TS, Peleganchuk AV, et al · · 2022 · cited 7× · PMID 35560143 · DOI 10.1371/journal.pone.0267384
Lumbar MRI and Back Pain After Failed Conservative Treatment: The RuDDS Study.
Leonova O, Elgaeva E, Berdnikova A, Tsepilov Y, et al · · 2026 · PMID 40901806 · DOI 10.1177/21925682251373046
Protocol for disease-oriented Russian disc degeneration study (RuDDS) biobank facilitating functional omics studies of lumbar disc degeneration
Leonova ON, Elgaeva EE, Golubeva TS, Peleganchuk AV, et al · · 2021 · DOI 10.1101/2021.03.07.21253070

Verify or expand the search:

Other trials of Non-interventional

Trials testing the same drug.

NCT06798298 — A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells · recruiting
NCT06746883 — A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacte · recruiting
NCT06622798 — Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients · recruiting
NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
NCT06277037 — Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) · recruiting

Other recruiting trials for Intervertebral Disc Degeneration

Currently open trials in the same condition.

NCT07168603 — EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease · Phase 1, PHASE2 · recruiting
NCT06342765 — Safety and Performance of the SpineVision Posterior Fixation Systems in Thoracolumbar Spinal Treatment · recruiting
NCT05299762 — A Post Market Surveillance on INFUSE Bone Graft · recruiting
NCT05648474 — Intraoperative Monitoring for the Lateral Lumbar Interbody Fusion Procedure · recruiting
NCT05997121 — Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease · recruiting

Other Novosibirsk State University trials

Trials by the same sponsor.

NCT03865355 — Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04600544 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novosibirsk State University
Last refreshed: 24 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04600544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing